NasdaqGS:CRNXPharmaceuticals
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility
Recent share performance and business snapshot
Crinetics Pharmaceuticals (CRNX) has drawn investor attention after a weak month for the share price, with the stock showing negative returns over the past month and past 3 months despite a positive 1 year total return.
The clinical stage company focuses on rare endocrine diseases, with its lead candidate Paltusotine in Phase 3 trials and several earlier stage programs. This context may influence how investors weigh recent share price moves...